Investor Centre
Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
2022 Interim Results Presentation

09 - December - 2022
Latest corporate presentation following publication of the interim results for 2022-23.
Stalicla Licensing Deal
10 - October - 2022Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla
Evgen InvestorMeet - Interim Results 2022-23
09 - December - 2022CEO Dr Huw Jones and CFO Richard Moulson provide an update following publication of the interim results for 2022-23.
Company | Analyst |
---|---|
finnCap | Mark Brewer |
Major Shareholder
Current Stakeholder | Number of shares | Percentage holding |
---|---|---|
J. R. Kight | 33,100,000 | 12.0% |
AXA Framlington | 23,848,884 | 8.7% |
Octopus Investments | 21,875,000 | 8.0% |
SPARK Impact | 16,186,446 | 5.9% |
Seneca Investment Managers | 14,932,071 | 5.4% |
Chelverton Asset Management | 12,500,000 | 4.5% |
RAB Capital | 8,750,000 | 3.2% |
Newlands Capital | 8,314,815 | 3.0% |
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.